BUSINESS● ELEVATEDJun 27 · Jun 27, 2026, 4:28 PM
Why is the US targeting Germany's drug industry?
DW News [en]
A new trade probe is reigniting a long-running clash over who should pay for medical innovation. Washington argues Germans benefit from lower prices while US patients shoulder a disproportionate share of the costs.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS22m agoWill Argentina’s citizenship scheme lure property buyers from mainland China and Hong Kong?South China Morning PostBUSINESS1h agoHong Kong’s art trading hub ambitions rest on more than headline salesSouth China Morning Post